Paul Gross Biography and Net Worth

Insider of Clovis Oncology

Paul E. Gross has served as our Executive Vice President, General Counsel since February 2019 and, prior to that, as our Senior Vice President, General Counsel since January 2016. Mr. Gross also served as our Chief Compliance Officer from January 2016 to February 2020. Previously, Mr. Gross was the General Counsel for Datalogix, Inc. from 2014 to 2015 and from 2015 to 2016 was a Director of Business Operations with Oracle Corporation following the acquisition of Datalogix by Oracle in 2015. From 2010 to 2014, Mr. Gross was founding partner of the law firm Gross Cutler Seiler Dupont LLC and prior to that a partner with Cooley LLP. Mr. Gross earned a Bachelor of Science degree from the U.S. Naval Academy and a Juris Doctor from King Hall School of Law, University of California, Davis.

What is Paul Edward Gross' net worth?: The estimated net worth of Paul Edward Gross is at least $0.00 as of June 3rd, 2021. Mr. Gross owns 55,539 shares of Clovis Oncology stock worth more than $0 as of April 25th. This net worth estimate does not reflect any other investments that Mr. Gross may own. Learn More about Paul Edward Gross' net worth.
How do I contact Paul Edward Gross?: The corporate mailing address for Mr. Gross and other Clovis Oncology executives is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. Clovis Oncology can also be reached via phone at 303-625-5000 and via email at [email protected]. Learn More on Paul Edward Gross' contact information.
Has Paul Edward Gross been buying or selling shares of Clovis Oncology?: Paul Edward Gross has not been actively trading shares of Clovis Oncology during the last quarter. Most recently, Paul Edward Gross sold 231 shares of the business's stock in a transaction on Thursday, June 3rd. The shares were sold at an average price of $5.63, for a transaction totalling $1,300.53. Following the completion of the sale, the insider now directly owns 55,539 shares of the company's stock, valued at $312,684.57. Learn More on Paul Edward Gross' trading history.
Who are Clovis Oncology's active insiders?: Clovis Oncology's insider roster includes Paul Gross (Insider), Thomas Harding (Insider), Gillian Ivers-Read (Insider), and Lindsey Rolfe (Insider). Learn More on Clovis Oncology's active insiders.

Paul Edward Gross Insider Trading History at Clovis Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/3/2021	Sell	231	$5.63	$1,300.53	55,539
9/3/2020	Sell	435	$5.30	$2,305.50	26,902
8/3/2020	Sell	2,506	$5.92	$14,835.52	25,871
5/5/2020	Sell	2,213	$8.10	$17,925.30	21,901
6/4/2019	Sell	453	$15.07	$6,826.71	4,207

Paul Edward Gross Buying and Selling Activity at Clovis Oncology

Clovis Oncology Company Overview

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Today's Range

Now: N/A

50 Day Range

MA: $0.43

$0.08

$1.09

2 Week Range

Now: N/A

Volume

1,155,888 shs

Average Volume

8,875,886 shs

Market Capitalization

$11.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.24

Bitcoin Rockets To Record High But Buy THIS Instead

From Paradigm Press | Ad

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.